• Explore /
  • Poster
  • / Camrelizumab plus apatinib for immunochemotherapy-treated advanced esophageal squamous cell carcinoma: Preliminary results of cohort 2 in CAP 02 study.

Camrelizumab plus apatinib for immunochemotherapy-treated advanced esophageal squamous cell carcinoma: Preliminary results of cohort 2 in CAP 02 study.

Abstract Poster

Authors

null

Feng Wang

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China;

Feng Wang , Junsheng Wang , Xiangrui Meng , Zhiquan Luo , Jin Xia , Yong-Gui Hong , Ping Lu , Yinghua Ji , Zheng-Zheng Shan , Qingxia Fan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03736863

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 384)

DOI

10.1200/JCO.2023.41.4_suppl.384

Abstract #

384

Poster Bd #

G6

Abstract Disclosures

Similar Posters

First Author: Xiangrui Meng

First Author: Feng Wang

First Author: Huaying Wang

First Author: Chengzhi Zhou